| Date Filed | Type | Description |
| 02/14/2022 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 0% stake in Kindred Biosciences, Inc. |
| 02/14/2022 |
SC 13G/A
| AMERIPRISE FINANCIAL INC reports a 0% stake in Kindred Biosciences, Inc |
| 09/13/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/07/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 09/02/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/31/2021 |
SC 13D/A
| GAMCO INVESTORS, INC. ET AL reports a 0% stake in Kindred Biosciences, Inc. |
| 08/30/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/30/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/30/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/30/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/30/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/30/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/30/2021 |
8-K
| Quarterly results |
| 08/30/2021 |
SC 13D/A
| Elanco Animal Health Inc reports a 100% stake in Kindred Biosciences, Inc. |
| 08/27/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/26/2021 |
8-K
| Quarterly results |
| 08/09/2021 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 08/09/2021 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 08/05/2021 |
SC 13D/A
| GAMCO INVESTORS, INC. ET AL reports a 4.4% stake in Kindred Biosciences, Inc. |
| 08/05/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 08/02/2021 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 08/02/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/02/2021 |
8-K
| Other Events Interactive Data |
| 07/21/2021 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 07/12/2021 |
SC 13G/A
| BlackRock Inc. reports a 1.8% stake in Kindred Biosciences, Inc. |
| 07/09/2021 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 06/30/2021 |
SC 13D/A
| Magnetar Financial LLC reports a 7.6% stake in KINDRED BIOSCIENCES INC. |
| 06/25/2021 |
SC 13D
| Elanco Animal Health Inc reports a 15.1% stake in Kindred Biosciences, Inc. |
| 06/25/2021 |
SC 13D
| Magnetar Financial LLC reports a 6.5% stake in KINDRED BIOSCIENCES, INC. |
| 06/24/2021 |
SC 13G
| INTEGRATED CORE STRATEGIES LLC reports a 5.7% stake in KINDRED BIOSCIENCES, INC. |
| 06/17/2021 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/16/2021 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/16/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/16/2021 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
|